According to 36Kr.com, Clinflash Healthcare Technology ("Clinflash"), a subsidiary of China's leading contract research organization Hangzhou Tigermed Consulting, has raised tens of millions of yuan in a Series A funding round from Qiming Venture Partners. Proceeds of this financing will be used for the development of clinical trial systems, team optimization, and market expansion.

Founded in 2014, Clinflash was approved as a national high-tech enterprise in 2018. The company provides cloud solutions and related services for clinical research and holds a number of core technologies and exclusive patents. Since its establishment, Clinflash has developed the "Clinflash" series of clinical trial systems, including the EDC electronic data acquisition system, the IRT randomized and supply management system, and the Safety drug alerting system.

This series of systems have been applied in large-scale registration and post-marketing clinical research at home and abroad. Clinflash has cooperated with more than 300 domestic and international leading pharmaceutical companies and CRO, providing services for more than 600 clinical research projects, covering innovation drugs, generic drugs, medical apparatus and instruments, in vitro diagnostics and other fields.

The Clinflash EDC and Clinflash IRT systems have been widely used in the field of innovative drugs, with several phase III clinical studies successfully having been completed, and many products successfully applied for NDA and marketed.

The Clinflash Safety system is also used by well-known pharmaceutical and medical device companies. The system meets the E2B R3 standard and is applied in clinical trials and the submission of safety reports and signal monitoring of individual cases after marketing.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management. Qiming Venture Partners invests in information technology, new consumer business patterns, and the healthcare sector.